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Background: Conventional p38α inhibitors have limited efficacy in rheumatoid arthritis, possibly because p38
blockade suppresses the counter-regulatory mechanisms that limit inflammation. In contrast, targeting the upstream
MAP kinase kinases, MKK3 and MKK6, partially maintains p38-mediated anti-inflammatory responses in bone
marrow-derived macrophages (BMDM). In this study, we explored the mechanisms that preserve anti-inflammatory
gene expression by evaluating differential regulation of IL-10 and p38-dependent anti-inflammatory genes in MKK3−/−,
MKK6−/−, and p38 inhibitor-treated wildtype cells.
Methods: BMDM from wild type (WT), MKK3−/−, and MKK6−/− mice were pre-treated with p38 inhibitor SB203580
(SB), JNK inhibitor SP600125 (SP), and/or ERK inhibitor PD98059 (PD) and stimulated with LPS. Supernatant protein levels
were measured by multiplex bead immunoassay. mRNA expression was determined by qPCR and protein expression
by Western blot analysis. De novo IL-10 mRNA synthesis was quantified in cells treated with ethynyl-uridine and LPS
followed by reverse transcription and qPCR. mRNA half-life was measured in LPS-treated cells that were then incubated
with actinomycin D ± SB203580.
Results: Pre-treatment of WT BMDM with p38 inhibitor significantly reduced IL-10 production in the three groups,
while ERK and JNK inhibitors had minimal effects. IL-10 production was significantly decreased in MKK3−/− BMDM
compared with either WT or MKK6−/− cells. IL-10 mRNA expression was modestly reduced in MKK3−/− BMDM but
was preserved in MKK6−/− cells compared with WT. De novo IL-10 mRNA synthesis was inhibited in MKK3−/− and p38
inhibitor pre-treated cells, but not MKK6−/− cells compared with WT. IL-10 mRNA half-life was markedly reduced in
p38 inhibitor-treated WT cells while MKK-deficiency had minimal effect. DUSP1 mRNA levels were preserved in
MKK-deficient cells but not in p38 inhibitor-treated WT cells. Tristetraprolin mRNA and protein levels were
reduced in p38 inhibitor-treated WT cells compared with MKK6−/− cells.
Conclusion: Unlike p38-inhibition, the absence of MKK6 mostly preserves IL-10 and TTP protein expression in
BMDM. MKK6-deficiency also spares DUSP1 and IL-1RA, which are key negative regulators of the inflammatory
response. Together, these data suggest that MKK6 is a potential therapeutic target in RA.
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Background
Several highly specific p38α inhibitors that competitively
bind the ATP binding pocket have been developed and
evaluated in RA [1]. Despite promising pre-clinical data,
these compounds show little therapeutic efficacy [2,3].
Several studies suggested that the unexpected lack of bene-
fit in RA is due to the role of p38 in limiting inflammation,
which might be blocked by the p38 inhibitor [4]. For* Correspondence: dhammaker@ucsd.edu
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article, unless otherwise stated.instance, p38α down-regulates its own activity by inducing
expression of dual specificity phosphatase 1 (DUSP1),
which de-phosphorylates and inactivates p38 and JNK
[5,6]. p38α also phosphorylates TAB1, leading to the in-
hibition of TAK1, a MAP3K that activates the p38 and
JNK pathways [7]. p38α decreases MKK6 mRNA stability
under basal conditions, providing negative feedback to
its own signaling cascade [8]. Perhaps most relevant to
the resolution of inflammation, p38α is required for the
synthesis of IL-10, a potent anti-inflammatory cytokine
that inhibits IL-6 and TNF expression [9] as well astral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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promotes the degradation of inflammatory cytokine
mRNA [10,11]. Blocking these anti-inflammatory roles
of p38α during and after inflammation might explain
the lack of long-term efficacy of p38α inhibitors.
Our previous studies demonstrated that targeting either
MKK3 or MKK6, which are the primary upstream activa-
tors of p38, might be superior to p38α blockade by pre-
serving these anti-inflammatory responses. We recently
showed that p38αlysM mice, which lack p38α expression in
macrophages, have increased arthritis severity in passive
serum transfer and antigen-induced arthritis models [12].
In contrast, MKK3- or MKK6-deficiency reduces arthritis
severity and joint destruction [13,14]. In addition, MKK3,
but not MKK6, is required for optimal p38 activation in
synovitis, whereas MKK6-deficiency is associated with
lower IL-6, IL-17 and anti-collagen antibody production
[14,15]. In bone marrow-derived macrophages (BMDM),
p38 inhibition blocks IL-10 and DUSP1 expression while
MKK-deficiency partially spared these anti-inflammatory
responses [12]. It is not clear why the absence of p38α
compared with MKK3 or MKK6 yields such divergent
anti-inflammatory effects. In this study, we explored po-
tential mechanisms by which p38 inhibition and MKK3-
or MKK6-deficiency differentially regulates IL-10 pro-
duction in BMDM. These data suggest that MKK6 is an
attractive therapeutic target in the p38 pathway that
preserves multiple p38-dependent anti-inflammatory
pathways.
Methods
Bone marrow-derived macrophage culture (BMDM)
Bone marrow was isolated from the femur and tibia of
DBA.1 WT, MKK3−/− and MKK6−/− mice and cultured
in DMEM supplemented with 10% FCS and 20% L929-
conditioned medium. After 7 days, the adherent BMDM
were harvested, counted, and plated for use in experiments
described below.
Gene and protein expression
For gene expression assays, BMDM were treated with p38
inhibitor SB203580 (SB, 3 μM), JNK inhibitor SP600125
(SP, 20 μM) and/or ERK inhibitor PD98059 (PD, 100 μM)
(Calbiochem) for 1 h prior to LPS stimulation (100 ng/ml,
Invivogen). After 4 hours, mRNA was isolated and proc-
essed for quantitative PCR. Expression of DUSP1 and
TTP was evaluated 1 h after LPS stimulation and IL-1RA
after 4 h. For cytokine analysis, cells were stimulated with
LPS for 24 h and the cell supernatants were assayed using
multiplex immunoassay (Bio-Rad).
Western blot analysis
BMDM were serum-starved overnight and stimulated
with LPS (100 ng/ml) for various time points. The cellswere lysed and 100 μg of lysate was subjected to SDS-
PAGE. The proteins were transferred to a PVDF mem-
brane and Western blot analysis was performed using
anti-phospho p38 (Pp38) antibody (cat #9216, Cell Sig-
naling Technology), total p38 antibody (cat #8690, Cell
Signaling Technology), anti-β actin (cat #sc-1616, Santa
Cruz Biotechnology) and anti-TTP antibody (a kind gift
of Dr. Perry Blackshear, National Institute of Environ-
mental Health Sciences, North Carolina, US).
mRNA decay
After 4 h of LPS stimulation, WT (n = 6), MKK3−/− (n = 3),
and MKK6−/− (n = 3) BMDM were treated with actinomy-
cin D (10 μg/ml) for various times and IL-10 mRNA levels
were analyzed by qPCR (Applied Biosystems) and normal-
ized to β-actin. To determine the effect of p38 inhibitor
on mRNA decay, WT cells were treated with SB (3 μM)
after LPS stimulation (WT SB post) and mRNA expres-
sion was assayed as described above.
Nascent RNA transcription rate
De novo mRNA synthesis was measured in WT, MKK3−/−,
and MKK6−/− BMDM treated with ethynyl-uridine with or
without LPS for 1 h. The RNA was quantified and biotinyl-
ated using Click-iT Nascent RNA capture kit (Invitrogen).
Nascent RNA was isolated using streptavidin-magnetic
beads. Reverse transcription was performed using Super-
Script VILO cDNA synthesis kit (Invitrogen) and IL-10
expression was measured by qPCR and presented as fold
of LPS-treated WTcells.
Statistical analysis
Comparisons between WT, MKK3−/−, and MKK6−/−
cells were analyzed by two-way or one-way ANOVA and
Tukey or Dunnett multiple comparison tests, unless
otherwise stated. Data were analyzed using GraphPad
Prism 6.0 and the comparisons were considered statisti-
cally significant if p < 0.05.
Results
Regulation of IL-10 protein and gene expression in
MKK-deficient or p38 inhibitor- treated BMDM
We first evaluated IL-10 production in LPS-stimulated
WT, MKK3−/− and MKK6−/− BMDM and compared it
to cells pre-treated with the p38 inhibitor (SB) (Figure 1a).
IL-10 protein expression was induced by LPS but was
significantly lower in MKK3−/− (p < 0.0001, n = 3/group)
compared with either WT or MKK6−/− BMDM. MKK6−/−
cells had only modest reduction in IL-10 levels compared
with WT cells. As expected, the p38 inhibitor significantly
reduced IL-10 in all three groups compared with their re-
spective LPS controls while JNK and ERK inhibitors had
no significant effect on LPS-induced IL-10 production by
WT, MKK3−/− and MKK6−/− cells. Combination of SP
Figure 1 Regulation of IL-10 protein and gene expression in MKK-deficient or p38 inhibitor-treated BMDM. (a) IL-10 protein levels were
significantly reduced in MKK3−/− compared with MKK6−/− or WT cells. MKK6-deficiency partially preserved IL-10 expression compared with WT
cells. Treatment with the p38 inhibitor significantly decreased IL-10 production in all three groups while JNK or ERK inhibition showed no major
effects (*p < 0.05). (b) IL-10 mRNA expression was modestly reduced in MKK3−/− cells compared with WT or MKK6−/− cells. As with protein
expression, p38 inhibitor reduced IL-10 mRNA expression in WT, MKK3−/− and MKK6−/− cells but JNK inhibitor showed minimal effect.
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treated cells. IL-10 mRNA expression was modestly
reduced in MKK3−/− compared with WT or MKK6−/−
cells (Figure 1b). However, p38 inhibition significantly de-
creased IL-10 mRNA expression in WT, MKK3−/− and
MKK6−/− BMDM while JNK blockade did not have a
major effect. These results show that p38, but not JNK or
ERK, regulates IL-10 production in BMDM. More import-
antly, deficiency of MKK6 and, to a lesser extent MKK3,
partially maintains IL-10 expression compared with direct
p38 inhibition.
Transcriptional regulation of IL-10 in MKK-deficient
BMDM
Since IL-10 expression is regulated transcriptionally and
post-transcriptionally, the effect of MKK-deficiency or
p38 inhibition on IL-10 transcription rate was evaluated.
Labeled nascent mRNA from p38 inhibitor-treated WT
cells and MKK3−/− or MKK6−/− cells was isolated, and
assayed by qPCR (Figure 2a). The p38 inhibitor as well
as MKK3-deficiency significantly decreased de novo
LPS-induced IL-10 transcription rate compared withWT LPS control. However, IL-10 transcription was com-
parable in MKK6−/− cells and WT cells, which is con-
sistent with our gene expression and protein data.
Post-transcriptional regulation of IL-10 in MKK-deficient
BMDM
IL-10 mRNA transcript stability in MKK-deficient cells
was determined by comparing IL-10 decay rates in WT,
MKK3−/−, and MKK6−/− cells (Figure 2b). IL-10 mRNA
decay was rapid, with half-life of 40 minutes for MKK6−/−,
46 minutes for MKK3−/− and 54 minutes for WT BMDM.
In WTcells treated with p38 inhibitor (WT SB post), IL-10
mRNA half-life of 30 minutes was significantly lower than
in WT cells. These data suggest that unlike p38 inhibition,
IL-10 expression in MKK3- or MKK6-deficient BMDM is
primarily regulated at the transcriptional level but not by
altering mRNA degradation.
Effect of p38 inhibitor or MKK-deficiency on the expression
of other anti-inflammatory molecules
We then determined if the effects of MKK-deficiency on
IL-10 could be generalized to the expression of other
Figure 2 Transcriptional and post-transcriptional regulation of
IL-10 expression. (a) De novo IL-10 transcription rate was significantly
inhibited in p38 inhibitor-treated WT and MKK3−/− cells compared
with WT control. MKK6−/− cells expressed IL-10 at a rate comparable to
WT control (*p < 0.05). (b) IL-10 mRNA decay in MKK-deficient cells
was comparable to WT control. p38 inhibitor-treated WT cells
showed a significantly higher rate of IL-10 degradation compared
with WT control.
Figure 3 Regulation of other p38-dependent anti-inflammatory gene
inhibitor-treated WT cells compared with WT control but not in MKK-defici
reduced in the presence of the p38 inhibitor and MKK3−/− cells but not MKK
p38 phosphorylation in MKK3−/− BMDM but not MKK6−/− BMDM. TTP prote
modestly elevated in MKK3−/− cells.
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As expected, DUSP1 expression in p38 inhibitor-treated
WT group was significantly lower than control (p = 0.005,
n = 3, Figure 3a). In contrast, DUSP1 expression in
MKK3−/− and MKK6−/− cells was comparable to WT.
Expression of tristetraprolin (TTP) and IL-1 receptor
antagonist (IL-1RA) mRNA was significantly reduced in
p38 inhibitor-treated and MKK3−/− cells compared with
WT, while MKK6−/− expressed WT levels of both genes.
Together, these data show that p38 inhibition, but not
MKK6 deficiency, significantly blocks DUSP1, IL-1RA and
TTP expression. Since TTP is an important negative regu-
lator of proinflammatory cytokines, we next evaluated the
effect of MKK-deficiency and p38 inhibition by Western
blot analysis (Figure 3b). P-p38 levels were lower in
MKK3−/− cells compared with WT or MKK6−/− cells.
Consistent with our previous studies, MKK3 is the pri-
mary kinase for phosphorylating p38 in BMDM [12]. Al-
though MKK6 is not required for p38 phosphorylation, it
is necessary for the efficient induction of cytokines such
as IL-6 in BMDM, indicating that MKK6-deficiency has
effects downstream of p38 phosphorylation (Additional
file 1: Figure S1) [16]. TTP expression peaked after 2 h of
exposure to LPS in the WT and MKK−/− groups, al-
though surprisingly, MKK3−/− cells showed modestly
higher levels of TTP. Others have shown that TTP deg-
radation is mediated by phosphorylation of MAPKAPK2
by p38 [11]. It is likely that reduced P-p38 levels in
MKK3−/− cells reduces MAPKAPK2 phosphorylation
leading to elevated TTP levels. Expression of TTP was
markedly decreased in p38 inhibitor treated WT cells, as
shown previously [10]. Together, these data show that
p38 inhibitor and MKK6-deficiency can differentially
regulate TTP mRNA and protein in BMDM.s. (a) DUSP1 mRNA expression was significantly reduced in p38
ent cells (*p < 0.05). TTP and IL-1RA mRNA levels were significantly
6−/− cells compared with WT. (b) Western blot analysis showed reduced
in expression was similar in WT, MKK3−/− and MKK6−/−, although it was
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The p38 pathway regulates the resolution of inflammatory
responses by increasing expression of anti-inflammatory
cytokines to promote wound healing and homeostasis.
Blocking p38 inhibits the expression of IL-10 and p38-
dependent anti-inflammatory genes such as DUSP1, TTP,
and IL-1RA. In contrast, MKK6-deficiency allows partial
or full induction of IL-10 and TTP, which negatively regu-
late the inflammatory cascade. These data suggest that
blocking MKK6 might be a potential therapeutic target for
inflammatory diseases such as RA that avoids some of the
limitations of a conventional p38 inhibitor.
Additional file
Additional file 1: Figure S1. Effect of MKK3- and MKK6-deficiency on
IL-6 promoter activity. WT, MKK3−/− and MKK6−/− BMDM were
transfected with 2 μg of IL-6 promoter construct (pGL4.10-IL-6/luc, a kind
gift of Dr. Peter Sporn, Northwestern University, Chicago, IL) and 0.2 μg of
Renilla construct and stimulated with 100 ng/ml LPS for 24 h. The cells
were lysed and the luciferase activities were measured using Dual luciferase
reporter assay system (Promega). The ratio of firefly/renilla luciferase was
determined for 3 different BMDM lines/group. The data are represented as
average fold of WT LPS.
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